ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. Our specialised business model connects science, finance and commerce to accelerate early-stage drug development.
We identify proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
ValiRx has been operating since 2000 and listed on the AIM Market of the London Stock Exchange in October 2006, trading under the ticker symbol: VAL.
The Company has an expanding pipeline of pre-clinical and clinical assets. As well as accelerating the development of the existing product portfolio, ValiRx is creating a pipeline of reduced risk, early stage compounds for further development and partnering.
ValiRx is a parent company to a growing portfolio of Special Purpose Vehicle companies (SPVs). The structure and purpose of each is unique and optimised per project.
ValiSeek is an early example of the SVP structure:
ValiSeek is ValiRx's Joint Venture Company, formed with Tangent Reprofiling Limited (a SEEK group company) in 2014 with the purpose of progressing VAL401 through the pilot Phase 2 clinical trial. ValiRx currently holds 55% of ValiSeek.